Cases by country, the UK and NHS pathway and other country lenses, the expert centres with trials on record, and the centres named on this cancer's subtypes.
Site: Head and neck (lip/oral, salivary, oro-, naso-, hypopharynx, larynx). World: 947,211 new cases a year.
| # | Country | New cases | Incidence ASR |
|---|---|---|---|
| 1 | India | 247,924 | |
| 2 | China | 145,603 | |
| 3 | United States of America | 63,440 | |
| 4 | Bangladesh | 36,808 | |
| 5 | Indonesia | 33,603 | |
| 6 | Brazil | 29,669 | |
| 7 | Japan | 26,319 | |
| 8 | Russian Federation | 26,149 | |
| 9 | Pakistan | 24,652 | |
| 10 | France (metropolitan) | 17,837 |
Sum of six GLOBOCAN sites. Counts and age-standardised rates add; cumulative risk is left blank.
Country-level death counts mix every stage, subtype and year of diagnosis, and reflect access to screening and treatment as much as the disease. Survival differs by stage, subtype and year; the cancer page above leads with what can be done.
| # | Country | New cases | Deaths |
|---|---|---|---|
| 1 | India | 247,924 | 137,925 |
| 2 | China | 145,603 | 80,437 |
| 3 | United States of America | 63,440 | 13,925 |
| 4 | Bangladesh | 36,808 | 20,850 |
| 5 | Indonesia | 33,603 | 21,155 |
| 6 | Brazil | 29,669 | 15,402 |
| 7 | Japan | 26,319 | 9,561 |
| 8 | Russian Federation | 26,149 | 14,555 |
| 9 | Pakistan | 24,652 | 15,568 |
| 10 | France (metropolitan) | 17,837 | 5,333 |
World: 947,211 new cases and 482,428 deaths a year (GLOBOCAN 2022).
Houston · cancer center | United States | 0 | 6,742 | 95,559 | #2 | ||
Seoul · hospital | South Korea | none recorded | 0 | 1,319 | 17,459 | #3 | |
Rochester, MN · hospital | United States | 0 | 4,572 | 48,202 | #5 | ||
Baltimore · cancer center | United States | 0 | 2,962 | 42,161 | #10 | ||
Milan · cancer center | Italy | none recorded | 0 | 1,252 | 21,584 | #11 | |
Berlin · university | Germany | none recorded | 0 | 1,567 | 18,047 | #12 | |
Boston · cancer center | United States | 0 | 4,333 | 74,896 | none recorded | #15 | |
Boston · hospital | United States | 0 | 3,584 | 55,693 | #16 | ||
Heidelberg · cancer center | Germany | none recorded | 0 | 3,473 | 46,508 | #18 | |
Cleveland · hospital | United States | 0 | 2,275 | 29,951 | #20 | ||
Paris · cancer center | France | none recorded | 0 | 1,044 | 15,238 | #21 | |
Seoul · hospital | South Korea | none recorded | 0 | 820 | 10,449 | #22 | |
Manchester · cancer center | United Kingdom | none recorded | 0 | 105 | 2,179 | #23 | |
Shanghai · cancer center | China | none recorded | 0 | 1,684 | 18,710 | #55 | |
Guangzhou · cancer center | China | none recorded | 2 | 1,866 | 22,263 | none recorded | #60 |
These are the things we can measure; they are not a ranking of quality. Each column is a field on the institution record or a count over what OnCo has linked; a centre that treats many patients with Head and neck squamous cell carcinoma but is thinly recorded here will look small.
Not known: OnCo holds no case-volume or outcome figures for centres, so none are shown. Where a national audit or registry publishes them, the centre's page links to it. Default order: Newsweek rank, then trials for this cancer, then research output.
17 centres are named on one of the types below rather than on Head and neck squamous cell carcinoma itself. Grouped by the type that holds them; the full table for each sits on that type's page.